BioCatalystWatch
RADXWorkspace / RADX / OverviewCompany library
Radiopharm Theranostics Ltd logo

Radiopharm Theranostics Ltd

Radiopharm Theranostics Ltd (RADX)

Website

Price
Market cap
Next catalyst2H 2026RAD301 · Trial initiationCompany presentation ↗
Cash

Chart & Events

Candle interval

Core Clinical

RV01

4Ig-B7-H3 (CD276)

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

RAD204

PD-L1

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

RAD204

PD-L1

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

RAD402

KLK3 (PSA)

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

RAD101

FASN

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

RAD101

FASN

PreINDP1P2FilingApproved
Upcoming / outlook

RAD302

Integrin αvβ6

PreINDP1P2P3FilingApproved
Upcoming / outlook

RAD202

HER2

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

RAD202

HER2

Upcoming / outlook

  • Timing and evidence

RAD202

HER2

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

RV01

4Ig-B7-H3 (CD276)

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

RAD402

KLK3 (PSA)

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

RAD101

FASN

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

RAD101

FASN

PreINDP1P2FilingApproved
Upcoming / outlook

RAD204

PD-L1

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

RAD202

HER2

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Other pipelines

RAD301

Integrin αvβ6

PreINDP1P2P3FilingApproved
RAD301

Integrin αvβ6

PreINDP1P2P3FilingApproved
RV01

4Ig-B7-H3 (CD276)

PreINDP1P2P3FilingApproved
RV01

4Ig-B7-H3 (CD276)

PreINDP1P2P3FilingApproved
RV01

4Ig-B7-H3 (CD276)

PreINDP1P2P3FilingApproved
RV01

4Ig-B7-H3 (CD276)

PreINDP1P2P3FilingApproved
RV01

4Ig-B7-H3 (CD276)

PreINDP1P2P3FilingApproved
RAD102

PreINDP1P2P3FilingApproved
RAD102

PreINDP1P2P3FilingApproved
RV02

PreINDP1P2P3FilingApproved
RV03

PreINDP1P2P3FilingApproved

Partner / License out

LRRC15

PreINDP1P2P3FilingApproved

PD-L1

PreINDP1P2P3FilingApproved

History / paused

RAD301

Integrin αvβ6

HER2

PreINDP1P2P3FilingApproved

Financial position

Cash and cash equivalents

Source and basis

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Reported shares and borrowings

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

RADX PR & News

PR & News

RADX SEC archive